Overview of FDA Expedited Development and Approval Programs for Serious Conditions
Impact Pharmaceutical Services
MAY 4, 2022
In May of 2014 and February of 2019 , the FDA released final Guidance for Industry outlining the Agency’s policies and procedures regarding expedited development and review programs for new drugs and biologics intended to treat serious or life-threatening conditions. Category: Regulatory Affairs , Drug Development Consulting.
52 
Let's personalize your content